Clinical trial · Observational
Role of Programmed Death Ligand 1 in Colorectal Cancer
the Role of Programmed Death Ligand 1 in Diagnosis of Colorectal Cancer
NCT07088341CI-TRIAL-00092671SPDL1not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
1. \- Evaluation of diagnostic importance of soluble programmed death ligand-1 in patient with recently diagnosed as Colorectal cancer at different stages of disease . 2. Correlation of SPDL-1 level and clinco-pathological data of patients at presentation .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colo-rectal Cancer | Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| elisa | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Study the expression level of sPDL 1 in colorectal cancer by ELISA
- timeFrame
- baseline
- description
- Correlate the expression level of sPDL-1 and stage of disease
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria:Patients at South Egypt Cancer institute and Assuit University Hospital Recently diagnosed as colorectal cancer patients at different stages. 2\. Patients did not undergo colorectal surgery \- Exclusion Criteria: \-
References
Publications (1)
- BACKGROUNDShao W, Xu Y, Lin S, Gao J, Gao J, Wang H. The potential of soluble programmed death-ligand 1 (sPD-L1) as a diagnosis marker for colorectal cancer. Front Oncol. 2022 Aug 16;12:988567. doi: 10.3389/fonc.2022.988567. eCollection 2022. PMID 36052227